|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1998-4-22
|
|
pubmed:abstractText |
Systemic therapy for metastatic melanoma includes chemotherapy, either with dacarbazine alone or a multiagent combination regimen, and biologic therapy with recombinant interferon-alpha and/or recombinant interleukin-2. However, neither of these treatment options has produced long-term control of disease except on rare occasions. We have therefore developed a combined biochemotherapy program in an effort to improve long-term control of metastatic melanoma.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1081-4442
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3 Suppl 1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
S9-15
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9457387-Adolescent,
pubmed-meshheading:9457387-Adult,
pubmed-meshheading:9457387-Aged,
pubmed-meshheading:9457387-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9457387-Cisplatin,
pubmed-meshheading:9457387-Combined Modality Therapy,
pubmed-meshheading:9457387-Dacarbazine,
pubmed-meshheading:9457387-Drug Therapy, Combination,
pubmed-meshheading:9457387-Humans,
pubmed-meshheading:9457387-Immunotherapy,
pubmed-meshheading:9457387-Interferon-alpha,
pubmed-meshheading:9457387-Interleukin-2,
pubmed-meshheading:9457387-Melanoma,
pubmed-meshheading:9457387-Middle Aged,
pubmed-meshheading:9457387-Recombinant Proteins,
pubmed-meshheading:9457387-Survival Rate,
pubmed-meshheading:9457387-Treatment Outcome,
pubmed-meshheading:9457387-Vinblastine
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
|
|
pubmed:affiliation |
Melanoma Section, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
